Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC

NCT07412054 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

234

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib
DRUG: Pembrolizumab
DRUG: Branched-Chain Amino Acids

Sponsor

Fudan University